Clinical Trial Update: Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

View source ↗

Summary

This clinical trial is evaluating whether early response to first-line anti-PD-1 monotherapy in recurrent/metastatic head and neck squamous cell carcinoma, asse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• anti-PD-1 monotherapy (PD-1 inhibitor)

Snippet

Sponsor: University of Rome Tor Vergata | Conditions: Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma | Status: RECRUITING